Use of 177Lu prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer : Joint statement of the Austrian Society of Nuclear Medicine and Theranostics and the Austrian Society of Urology and Andrology
{{output}}
Prostate cancer (PCa) remains a leading cause of cancer-related morbidity and mortality in men. Over the past decades, the incidence has risen in all age groups. Prostate-specific membrane antigen (PSMA)-based theranostics, which involve the use of PSMA-target... ...
